Endometrial cancer: bleeding, biopsy, types and treatment

Endometrial cancer begins in the lining of the uterus, or womb. It differs from uterine sarcoma and from cervical cancer. Bleeding or spotting after menopause, or an unusual bleeding pattern before menopause, needs prompt assessment. Confidence is high in these disease and symptom distinctions. Diagnosis requires appropriate tissue assessment; treatment depends on the confirmed cancer, its extent, molecular findings, health and personal priorities. NHS womb-cancer overview; NCI anatomical distinction.

Table of contents

• Evidence summary
• What endometrial cancer is, and which uterine cancers differ
• Hormones, hyperplasia and inherited risk
• Symptoms, postmenopausal bleeding and screening limits
• Ultrasound, hysteroscopy and biopsy
• Pathology, molecular results and treatment planning
• Surgery, radiation and selected systemic treatment
• Safety during investigation and cancer treatment
• Fertility, menopause and sexual health
• Nutrition, supplements and follow-up care
• Research, evidence limits and questions about a trial
• Funding and source roles
• Frequently asked questions
• Sources and funding notes

Evidence summary

Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.

What endometrial cancer is, and which uterine cancers differ

The uterus has an inner lining called the endometrium and a muscular wall. Endometrial cancer starts in the lining; cancer arising in uterine muscle belongs to a different disease group, uterine sarcoma. The cervix is the lower opening of the uterus, but cervical cancer has its own diagnostic and treatment pathway. NCI definition, dated anatomy.

Endometrioid adenocarcinoma is the most common endometrial histology. Serous, clear-cell, mixed and other uncommon forms also occur. Uterine carcinosarcoma contains carcinomatous and sarcomatous elements but is included in the endometrial carcinoma framework, despite its historical sarcoma label. These distinctions affect specialist assessment. This overview does not establish complete care guidance for every rare histology. NCI professional classification.

Hormones, hyperplasia and inherited risk

Some endometrial cancers are associated with prolonged estrogen exposure without sufficient opposing progestin. Endometrial hyperplasia is abnormal thickening that is not itself cancer, although some forms can precede cancer. Obesity, metabolic factors, diabetes, reproductive history, certain medicines and inherited conditions can affect risk. Lynch syndrome is an important inherited-risk pathway. Do not assume every endometrial cancer is simply caused by estrogen. NCI risk and hyperplasia context.

Tell the clinician about relevant family cancers, Lynch syndrome, diabetes, past pelvic treatment, hormone therapy and tamoxifen use. Discuss which menopausal hormone treatment is appropriate for your situation. Do not stop prescribed tamoxifen or alter HRT because of a general risk list: the reason for treatment and its benefits also matter. Unusual bleeding still needs assessment. NHS guidance includes physical activity and weight-related health support, but these are not substitutes for evaluating symptoms or treating established disease. NHS risk context.

Symptoms, postmenopausal bleeding and screening limits

Symptoms can include bleeding or spotting after menopause, periods that are unusually heavy, bleeding between periods, and changed vaginal discharge. Pelvic or lower-back pain, pain during sex, a pelvic swelling, or changed bowel or bladder habits may also occur. Many noncancerous conditions cause these problems, but the explanation needs assessment. Do not postpone contact because bleeding seems embarrassing or because another condition previously explained it. A specialist referral means investigation is needed, not that cancer has already been confirmed. NHS symptoms.

Routine cervical screening samples or tests the cervix; it is not an endometrial-cancer screening test. A reassuring cervical result cannot rule out a problem in the uterine lining. NCI describes no standard routine endometrial screening test for the general population. Investigating abnormal bleeding is a diagnostic pathway, which differs from screening a person without symptoms. People with inherited risk need their own specialist plan; this guide does not prescribe a Lynch-syndrome surveillance interval or a screening scan for everyone. NCI screening boundaries.

Ultrasound, hysteroscopy and biopsy

Assessment can include transvaginal ultrasound, blood tests, hysteroscopy and sampling of the uterine lining. Ultrasound shows structures; biopsy provides tissue for a pathologist. The tests selected depend on symptoms and findings, so a referral does not mean every procedure is required. Ask what is being sampled, how results will reach you, and who arranges follow-up. Confirmed cancer may require additional imaging and specialist or genetic assessment. NHS diagnostic pathway.

A hysteroscope is a thin camera passed through the vagina and cervix to inspect the womb. A biopsy can be taken during the procedure. Pain can be substantial, so discuss analgesia, local anaesthesia, sedation or other available arrangements in advance. Tell the team about difficult examinations, relevant trauma and any possibility of pregnancy. Consent includes an explanation of the procedure, and you can ask to stop. Do not use a general leaflet to choose your own pain-medicine dose or to assume discomfort must simply be endured. NHS hysteroscopy and consent.

Tissue, scans and clinical information can be shared for a second opinion. Ask the specialist to distinguish the biopsy diagnosis, the tumour’s grade and its stage. An ultrasound measurement alone is not a complete cancer diagnosis or a basis for a home treatment decision. NCI diagnostic context, dated.

Pathology, molecular results and treatment planning

Specialists consider tumour type, extent and selected molecular findings together. The professional summary describes POLE, mismatch-repair, p53 and other molecular categories that can inform risk assessment and treatment decisions. A category does not supply a personal prognosis or treatment recipe. Ask which findings actually apply to your tumour. NCI molecular framework.

Tumour testing and testing for inherited cancer risk are different. A tumour result may prompt genetic counselling, but it does not replace assessment for an inherited syndrome. A blood or saliva test can examine inherited variants; counselling addresses the result and its implications for relatives. A variant of uncertain significance is not the same as a proven disease-causing variant. Share the actual report, family history and previous testing rather than relying on a commercial summary or assuming a negative result removes every risk. NCI inherited-risk testing.

Ask how the actual results affect your plan. This guide does not interpret personal genetic results or select medicines from one biomarker.

Surgery, radiation and selected systemic treatment

Surgery is often central to treating endometrial cancer. Depending on the findings, care may also involve radiation, chemotherapy, hormone therapy, immunotherapy or targeted medicines. The purpose may be treatment of localized disease, postoperative care, control of recurrent or advanced cancer, or symptom relief. Which options are suitable depends on the cancer and the person’s health; a list does not mean all should be combined. Report troubling symptoms during treatment rather than waiting for the next scheduled review. NHS treatment framework.

A hysterectomy removes the uterus, usually with the cervix in this setting. Removal of ovaries and fallopian tubes is a separate part of the proposed operation; lymph-node assessment may also be involved. Confirm exactly which structures are to be removed. Radiation can be delivered from an external machine or internally near the treatment area. This older native NCI page supports those basic distinctions only; its medicine examples and comparative safety language are not adopted as a current drug menu. NCI dated procedural overview.

These are attributed clinical care roles. Public summaries can include manufacturer-supported trials, and editorial review does not make those trials independently funded. No commercial product outcome estimate, medicine ranking, personal dose or treatment sequence is adopted here.

Safety during investigation and cancer treatment

After hysteroscopy, worsening bleeding, increasing abdominal pain, fever or unpleasant-smelling discharge needs urgent contact with the procedure service. Follow the instructions you were given. The possibility of infection or uterine injury means that deteriorating symptoms should not be assumed to be routine recovery. NHS procedure warning.

Some cancer treatments lower platelets and increase bleeding risk. Bleeding that will not stop, unexpectedly heavy bleeding, blood in vomit or stool, or new confusion or marked sleepiness needs prompt medical assessment and the team’s urgent plan. Review medicines and supplements that can affect bleeding before adding them. This guide does not provide a home waiting threshold or tell you to stop a prescribed blood thinner on your own. NCI serious bleeding warning.

Fever, chills or other signs of infection during cancer treatment require urgent oncology-team contact. Low infection-fighting white cells can make infection dangerous. Obtain the out-of-hours plan in advance and do not mask fever and wait for a routine visit. Individual instructions determine the assessment route; no universal temperature or prophylactic regimen is provided here. NCI dated infection warning.

Immunotherapy can affect healthy tissue and cause inflammation-related or allergic reactions. Problems may arise during treatment or afterwards. Ask which symptoms require immediate assessment for your actual medicine, and report new breathing problems or other concerning changes promptly. A general class label cannot predict which organs are affected or how serious a reaction will be. NCI immunotherapy safety context.

Fertility, menopause and sexual health

Discuss reproductive priorities before treatment. Removing the uterus prevents carrying a pregnancy; removal of both ovaries also affects eggs and ovarian hormone production. Radiation and systemic treatments may have additional reproductive effects. An oncofertility specialist can explain options and timing, without assuming that retaining organs is safe or possible for every cancer. Do not postpone necessary cancer care or begin a hormone-preserving regimen independently. Reduced fertility is not the same as a guarantee that pregnancy cannot occur during all forms of treatment. NCI fertility guidance.

Treatment can affect sexual comfort, vaginal tissue, hormones and intimacy. Tell the team about dryness, pain or other difficulties so appropriate support can be arranged. Menopausal hormone treatment, vaginal products and devices require assessment for the particular cancer and care received; a general symptom list does not establish their suitability. A sexual-health specialist can help with persistent problems. NCI sexual-health context.

Nutrition, supplements and follow-up care

Adequate nutrition supports recovery and general health, but restrictive diets, detox products and supplements are not substitutes for treating endometrial cancer. Ask for dietetic help when nausea, poor intake or bowel problems interfere with eating. A documented deficiency may need correction without implying an anticancer effect. The reviewed evidence does not establish an independent supplement cure or a recurrence-prevention course. NCI nutrition and unproved cures.

Give the oncology pharmacist a full ingredient list for medicines, herbs and supplements. Interactions depend on the exact cancer treatment and product. Do not assume natural means compatible, or that an ingredient studied in cancer cells is safe in a person receiving treatment. NCI ingredient-specific interactions.

A survivorship plan should record the pathology, operations, radiation and medicines received, who coordinates care, follow-up arrangements and possible late effects. Report new symptoms between visits. A plan after cancer treatment is different from population screening and should reflect your actual disease. This guide does not prescribe a universal scan or examination schedule. NCI follow-up care.

Research, evidence limits and questions about a trial

Ask about the comparator, meaningful patient outcomes, harms, sponsorship, costs and available care if you withdraw. Eligibility or participation does not guarantee benefit. A tumour response and a molecular finding do not automatically establish longer survival or better quality of life. NCI clinical-trial explanation.

No animal experiment, laboratory mechanism or testimonial supplies an independent human treatment verdict. The source map separates public educational funding, dated reviewer declarations, commercially supported activities and unresolved original-study sponsorship. Endometrial cancer is covered here as an illness overview; uncommon histologies and uterine sarcomas remain distinct scopes requiring further assessment.

Funding and source roles

The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.

Frequently asked questions

Is endometrial cancer the same as every uterine cancer? No. It begins in the uterine lining; uterine sarcoma is a separate family. Ask which histology your report names. NCI anatomy.

Can a normal cervical-screening result rule it out? No. Cervical screening is not endometrial-cancer screening. Abnormal bleeding still needs assessment. NCI screening distinction.

Does endometrial hyperplasia mean cancer? No. It is abnormal thickening, although some forms can precede cancer. The actual tissue findings determine the next step. NCI hyperplasia context.

Should small amounts of bleeding after menopause be ignored? No. Contact a clinician promptly for bleeding or spotting after menopause, even when it seems minor. NHS symptoms.

Sources and funding notes

Actual selected NCI and NHS originals were read. The former patient-PDQ URL redirects to a native November 2020 treatment page; it is not presented as a current patient PDQ derivation. Dated anatomy, procedure and safety sources support limited roles only. The current professional summary names Filippova and Stasenko. Separate dated manuscript/activity disclosures do not prove complete reviewer income or a page payment; colleagues’ interests are not assigned to them. Underlying medicine-trial funding is not cleared by public editorial review. No numerical prognosis, inherited-risk screening interval, personal hormone regimen, complete local drug menu or sponsored product outcome is adopted.

1. NCI endometrial professional PDQ — Selected histology, molecular context and named lead attribution.
2. NHS womb-cancer overview — Direct answer and anatomical context.
3. NHS womb-cancer symptoms — Abnormal bleeding and symptomatic assessment.
4. NHS womb-cancer causes — Risk factors and individualized hormone discussion.
5. NHS womb-cancer tests — Investigation, tissue and result follow-up.
6. NHS womb-cancer treatment — Broad specialist treatment framework.
7. NHS hysteroscopy — Consent, pain discussion and urgent procedure warning.
8. NCI endometrial definition — Dated anatomy only; uterine sarcoma distinction.
9. NCI native endometrial treatment — Dated procedure definitions only; drug menu and comparative safety excluded.
10. NCI native endometrial diagnosis — Dated selected diagnostic and second-opinion context only.
11. NCI endometrial risks and prevention — Hyperplasia, hormone context and selected inherited risks.
12. NCI endometrial screening — Cervical versus endometrial screening and symptom pathway; inherited-risk intervals excluded.
13. NCI inherited cancer-risk testing — Tumour versus inherited testing and uncertain-variant boundaries.
14. NCI bleeding and bruising — Selected serious treatment-related bleeding warning.
15. NCI immunotherapy side effects — Selected class-level inflammation warning, no risk estimate.
16. NCI infection and neutropenia — Urgent infection warning only; dated, no thresholds or prophylaxis menu.
17. NCI female fertility and cancer — Reproductive consequences and pretreatment referral.
18. NCI sexual health and cancer — Selected sexual-health and menopause context; dated.
19. NCI diets and supplements — Nutrition and unproved cure boundaries.
20. NCI dietary interactions patient PDQ — Ingredient-specific interaction caution; no efficacy estimates.
21. NCI follow-up care — Individual survivorship plan and symptom reporting.
22. NCI clinical-trial explanation — Consent and study-role explanation, not individual benefit.
23. Filippova: dated 2025 manuscript funding and author declarations — Reviewer identity and scoped financial declaration only; no surgical-score outcomes adopted.
24. Stasenko: SGO 2024 activity disclosure and commercial support — Dated reviewer declaration and activity funding only; no CME treatment claims adopted.
25. SGO current fundraising, corporate partners and office — Society financial routes and location only; no clinical claims.
26. NCI budget and appropriations, May 2026 — Institutional appropriation route only.
27. NCI Gift Fund and contribution routes, August 2025 — Separate gift route and office identity; no clinical evidence.
28. NCI PDQ editorial boards, November 2022 — Board independence, honoraria and conflict-disclosure scope.
29. NHS national content policy, October 2022 — Website funding and editorial safeguards only.

Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.